Huntington's Disease Treatment Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 0.76 Billion |
| Market Size (2029) | USD 1.35 Billion |
| CAGR (2024 - 2029) | 8.23 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Huntington's Disease Treatment Market Analysis
The Huntington's Disease Treatment Market size is estimated at USD 0.76 billion in 2024, and is expected to reach USD 1.35 billion by 2029, growing at a CAGR of 8.23% during the forecast period (2024-2029).
Huntington’s disease is an inherited disorder that results in the breakdown of nerve cells and impairs brain function. Factors such as the growing burden of Huntington’s disease and the surge in disease awareness levels are the key factors expected to drive the market growth during the forecast period. In addition, the growing efforts from manufacturers to develop effective treatment modalities for the condition are further expected to accelerate market growth.
The significant burden of Huntington’s disease around the globe is anticipated to accelerate demand for effective treatment regimens to manage the increased disease burden. For instance, according to a study published in an article published by the Journal of Huntington's Disease in June 2022, the burden of Huntington’s disease is on the rise in Canada, and there is a significant gap in the effective treatment of the disease.
The significant disease burden and unmet treatment needs are expected to create lucrative growth opportunities for market participants. This is expected to drive the development of advanced treatment options for the disease and stimulate market growth during the forecast period.
In addition, the increased efforts to develop promising treatments for all stages of Huntington’s disease and positive topline results from those investigational treatments are expected to support market growth during the forecast period. For instance, according to an article published by Pharmaceuticals in October 2023, several effective disease-modifying and symptomatic therapies paved their way through clinical trials to manage Huntington’s disease. In addition, these therapies promoted neurogenesis while improving brain function. Significant research and development efforts will likely foster industry expansion during the forecast period.
Moreover, the presence of a high volume of investigational candidates in the late phase of clinical trials and their anticipated launch during the forecast period is further likely to propel industry uptake. For instance, according to June 2024 data from the Clinical Trial Gov, there were around 69 studies in Phase II of the clinical trial, followed by 25 studies in Phase III. Thus, much higher volumes of investigational candidates and their projected launches during the forecast period are further expected to expedite industry expansion.
Also, several strategic initiatives market participants undertake to strengthen their business avenues are further expected to spur industry expansion during the forecast period. For instance, in April 2024, Skyhawk Therapeutics and Ipsen formed a collaboration agreement to develop small molecules that modulate RNA for rare neurological diseases, including Huntington’s disease.
In addition, positive topline results from investigational studies are further expected to propel market growth during the forecast period. For instance, in December 2023, uniQure NV published the results from the Phase I/II clinical trials of AMT-130 to manage Huntington’s disease. The overall results were very promising and showed disease stability in patients. Thus, such ongoing developments will likely accelerate market growth during the forecast period.
Thus, the surge in the burden of Huntington’s disease, increased demand for effective disease treatment, and growing research activities are expected to accelerate industry expansion during the forecast period. However, the high cost of developing effective treatment is expected to hamper the market's growth during the forecast period.
Huntington's Disease Treatment Market Trends
The Symptomatic Treatment Segment is Expected to Hold a Major Market Share During the Forecast Period
Symptomatic treatment of Huntington’s disease majorly focuses on motor impairment and chorea. Chorea remains the most prominent clinical feature of Huntington's disease, for which most therapeutic studies have been conducted. Relatively high availability and usage rates of symptom management therapeutics are expected to account for a significant share during the forecast period.
The rising need for multiple treatments and the intervention of a multispecialty care team for symptomatic management resulting in additional expenses may contribute to the development of the segment during the forecast period.
Key factors such as rising awareness campaigns and increasing product developments by various market players are expected to contribute to the growth of the segment. For instance, in May 2023, Neurocrine Biosciences Inc. reported complete findings from the Phase 3 KINECT-HD study investigating Valbenazine for treating Huntington's disease (HD) chorea. According to the company, Valbenazine showed a statistically significant improvement over the placebo in the Total Maximal Chorea (TMC) score.
In September 2022, Teva Pharmaceutical launched the Honestly HD website to help people better understand what to expect from Huntington's disease (HD) chorea, one of HD's most apparent and curable symptoms, and how to communicate to their doctor about maintaining independence.
Also, the surge in emphasis on symptomatic treatment of disease is further expected to accelerate segment expansion during the forecast period. For instance, according to an article published by Neurological Research and Practice in November 2023, treatment approaches such as pharmacotherapy and behavioral treatments should be individually adapted to manage several signs and symptoms of Huntington’s disease, including myoclonus, dystonia, and chorea. Thus, such increased emphasis on symptomatic treatment of disease is likely to augment segment expansion during the forecast period.
Therefore, key players' continuous R&D activities and awareness programs are expected to create lucrative opportunities for the segment during the forecast period.
North America is Expected to Hold a Significant Market Share During the Forecast Period
North America is expected to hold a significant market share during the forecast period due to the rising incidence of Huntington's disease, the presence of key players, and growing R&D funding by the government and private organizations. According to the April 2024 updated data of McGill University, Huntington’s disease has emerged as a significant disease in Canada, and it affects around 1 in 7,000 people in Canada. As Huntington's condition becomes more prevalent in this region, demand for efficient treatments is anticipated to rise, driving the growth of the target market throughout the forecast period.
Companies ' increasing product development and R&D activities are expected to fuel the market's growth during the forecast period. For instance, in June 2024, PTC Therapeutics Inc. published the Phase II interim results from the PIVOT-HD study of PTC518 in Huntington's disease (HD) patients. The results showed a significant decrease in mutant huntingtin (mHTT) protein in the blood. Thus, such increased product development activities and R&D activities by the market participants are likely to foster the development of new therapeutics, which is expected to boost market growth during the forecast period.
Moreover, the growing funding activities for Huntington’s disease research in the United States are further anticipated to accelerate market growth. For instance, according to 2024 updated data from the National Institute of Health, the estimated funding for Huntington’s disease research ramped from 49 million in 2024 to 50 million in 2025. Thus, the growing research funding for Huntington’s disease will likely accelerate the development of novel therapeutics, which, in turn, is projected to boost market growth during the forecast period.
Also, the growing regulatory approvals of novel therapeutics are further expected to propel the commercialization of innovative treatment options, further boosting market growth during the forecast period. For instance, in August 2023, the US Food and Drug Administration approved Neurocrine Biosciences Inc.’s INGREZZA (valbenazine) capsules for the management of chorea associated with Huntington's disease. Such approvals are anticipated to propel regional market growth during the forecast period.
As a result, the rising prevalence of the target disease, increased R&D, and supportive regulatory authorities are anticipated to contribute to the market expansion in this region during the forecast period.
Huntington's Disease Treatment Industry Overview
The Huntington's disease treatment market is competitive with several large, small, and medium-sized players. Some of the companies dominating the market are Pfizer Inc., Alnylam Pharmaceuticals Inc., Ceregene Inc., Prana Biotechnology Limited, Teva Pharmaceutical Industries Ltd, Ionis Pharmaceuticals, Neurocrine Biosciences Inc., Prilenia Therapeutics, Azevan Pharmaceuticals, and Lundbeck.
Huntington's Disease Treatment Market Leaders
-
Pfizer, Inc.
-
Alnylam Pharmaceuticals Inc.
-
Teva Pharmaceutical Industries Ltd.
-
Neurocrine Biosciences, Inc.
-
Ionis Pharmaceuticals
*Disclaimer: Major Players sorted in no particular order
Huntington's Disease Treatment Market News
- May 2024: The US Food and Drug Administration approved AUSTEDO XR of Teva Pharmaceuticals as a one-pill, once-daily treatment option for the treatment of Huntington’s disease (HD) chorea control and tolerable tardive dyskinesia.
- October 2023: Sage Therapeutics Inc.’s SAGE-718 received an orphan Drug Designation (ODD) from the US Food and Drug Administration to manage Huntington’s disease (HD).
Huntington's Disease Treatment Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Rising Incidence of Huntington's Disease in Developed Countries
- 4.2.2 Robust Funding for Research on Huntington's Disease
-
4.3 Market Restraints
- 4.3.1 High Cost for the Development of Treatment
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Type
- 5.1.1 Symptomatic Treatment
- 5.1.2 Disease-modifying Therapies
-
5.2 By Distribution Channel
- 5.2.1 Hospital Pharmacies
- 5.2.2 Retail Pharmacies
- 5.2.3 Online Pharmacies
-
5.3 By Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Pfizer Inc.
- 6.1.2 Alnylam Pharmaceuticals Inc.
- 6.1.3 Ceregene Inc. (Sangamo Therapeutics)
- 6.1.4 Teva Pharmaceutical Industries Ltd
- 6.1.5 Ionis Pharmaceuticals
- 6.1.6 Neurocrine Biosciences Inc.
- 6.1.7 Prilenia Therapeutics
- 6.1.8 Azevan Pharmaceuticals
- 6.1.9 Lundbeck
- 6.1.10 PTC Therapeutics
- 6.1.11 UniQure
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityHuntington's Disease Treatment Industry Segmentation
As per the scope of this report, Huntington's disease treatment covers various treatment modalities that are commercially available. It is a genetic disorder that mostly occurs between 30 and 50 years, leading to the degeneration of nerve cells in the brain.
The Huntington's disease treatment market is segmented by type and end user. By type, the market is segmented as symptomatic treatment and disease-modifying therapies. By end user, the market is segmented as hospital pharmacies, retail pharmacies, and online pharmacies. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America.
| By Type | Symptomatic Treatment | |
| Disease-modifying Therapies | ||
| By Distribution Channel | Hospital Pharmacies | |
| Retail Pharmacies | ||
| Online Pharmacies | ||
| By Geography | North America | United States |
| Canada | ||
| Mexico | ||
| By Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| By Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| By Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| By Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Huntington's Disease Treatment Market Research FAQs
How big is the Huntington's Disease Treatment Market?
The Huntington's Disease Treatment Market size is expected to reach USD 0.76 billion in 2024 and grow at a CAGR of 8.23% to reach USD 1.35 billion by 2029.
What is the current Huntington's Disease Treatment Market size?
In 2024, the Huntington's Disease Treatment Market size is expected to reach USD 0.76 billion.
Who are the key players in Huntington's Disease Treatment Market?
Pfizer, Inc., Alnylam Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Neurocrine Biosciences, Inc. and Ionis Pharmaceuticals are the major companies operating in the Huntington's Disease Treatment Market.
Which is the fastest growing region in Huntington's Disease Treatment Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Huntington's Disease Treatment Market?
In 2024, the North America accounts for the largest market share in Huntington's Disease Treatment Market.
What years does this Huntington's Disease Treatment Market cover, and what was the market size in 2023?
In 2023, the Huntington's Disease Treatment Market size was estimated at USD 0.70 billion. The report covers the Huntington's Disease Treatment Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Huntington's Disease Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Huntington's Disease Treatment Industry Report
Statistics for the 2024 Huntington’s Disease Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Huntington’s Disease Treatment analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
